About Origimm
Origimm is a Healthcare company based in Vienna (Austria) founded in 2014, and was acquired by Sanofi in December 2021. Biotech company focused on antigen and drug target discovery for prevention and treatment of dermatologicalinfectious conditions. The company was acqui-hired. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified.
Company details
Origimm was founded in 2014 in Vienna, Austria, as a biotech company specializing in antigen and drug target discovery. Operations center on the ProVaDis platform, which employs reverse functional screening for vaccine development. Current programs target prevention and treatment of acne vulgaris, as well as infections in medical implants, both linked to Propionibacterium acnes. The focus remains on dermatological and infectious disease applications.
- Headquarters Vienna, Austria
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website origimm.com
- Social LinkedIn Facebook
- Acquired by Sanofi (Dec 2021)
Funding Insights of Origimm
- Total Rounds 1
- Investors Count 1
All 1 funding rounds of Origimm with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2014 | Seed | – | – |
2 investors in total: 2 institutional.
Investors in Origimm
Origimm has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Sanofi and Austria Wirtschaftsservice.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Banking regulatory services are provided for Austrian financial institutions. | 2002 | aws.at | Vienna, Austria | |
Pharmaceutical and nutraceutical products are developed across seven therapeutic areas. | 1973 | sanofi.com | Paris, France |
Investor details for Origimm
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Origimm
3 dated milestones of Origimm across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Origimm is founded.
- Funding First funding round.
- Exit Acquired by Sanofi.
Web traffic of Origimm
Websites that share an audience with Origimm (origimm.com).
Websites whose visitors overlap most with Origimm. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| google.com | 100% | 85.8B | #1 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Origimm
Complete news archive for Origimm
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Origimm
Origimm was founded in 2014.
Origimm is headquartered in Vienna, Austria.
Origimm was founded in 2014 in Vienna, Austria, as a biotech company specializing in antigen and drug target discovery. Operations center on the ProVaDis platform, which employs reverse functional screening for vaccine development. Current programs target prevention and treatment of acne vulgaris, as well as infections in medical implants, both linked to Propionibacterium acnes. The focus remains on dermatological and infectious disease applications.
Origimm has 2 investors. Key investors include Sanofi, and Austria Wirtschaftsservice.
Yes. Origimm was acquired by Sanofi in December 2021.